ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma

We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Krakstad, Camilla, Tangen, Ingvild L., Hoivik, Erling A., Halle, Mari K., Berg, Anna, Werner, Henrica M., Ræder, Maria B., Kusonmano, Kanthida, Zou, June X., Øyan, Anne M., Stefansson, Ingunn, Trovik, Jone, Kalland, Karl-Henning, Chen, Hong-Wu, Salvesen, Helga B.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695070/
https://ncbi.nlm.nih.gov/pubmed/26308378
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars